December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY: JNJ )

147.05 +1.57 (+1.08%)
Official Closing Price Updated: 7:00 PM EDT, Jul 9, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 5,892,336
Open 145.67
Bid (Size) 147.05 (4)
Ask (Size) 147.20 (5)
Prev. Close 145.48
Today's Range 145.18 - 147.13
52wk Range 143.13 - 175.97
Shares Outstanding 2,628,679,824
Dividend Yield 3.24%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Johnson & Johnson Faces MedTech Challenges But Is 'On Track' To Meet 2024 Guidance: Goldman Sachs
Johnson & Johnson is set to release its Q2 2024 earnings on July 17. Analysts estimate $22.29 billion in sales and an EPS of $2.71. 
Via Benzinga
Emergent BioSolutions And Johnson & Johnson Resolve Claims Over COVID-19 Vaccine Manufacturing
Emergent BioSolutions and Janssen Pharmaceuticals settle disputes over SARS-CoV-2 vaccine manufacturing with a $50 million agreement, resolving all related claims and arbitration. 
Via Benzinga
Exposures COVID-19

Performance

YTD
-8.08%
-8.08%
1 Month
-0.05%
-0.05%
3 Month
-3.44%
-3.44%
6 Month
-9.02%
-9.02%
1 Year
-7.81%
-7.81%

More News

Read More
Looking At Johnson & Johnson's Recent Unusual Options Activity
Via Benzinga
7 Diversified Income Powerhouses for Lifelong Cash Flow
Via InvestorPlace
3 Rock-Solid Income Machines to Hold for Decades
Via InvestorPlace
Assessing Johnson & Johnson's Performance Against Competitors In Pharmaceuticals Industry
Via Benzinga
3 Dividend Aristocrats Now Cheaper Than During the 2008 Financial Crisis
Via InvestorPlace
What's Going On With Johnson and Johnson Shares Friday?
Via Benzinga
Nasdaq vs. Dow Jones: A Detailed Breakdown of Stock Indexes
Via MarketBeat
Topics Stocks
Exposures US Equities
FDA Favorites: 3 Biotech Stocks on the Verge of Major Approvals
Via InvestorPlace
Exposures Product Safety
Upcoming Stock Spinoffs: Should You Pounce or Pass?
Via InvestorPlace
7 Blue-Chip Cash Cows to Milk for Steady Income
Via InvestorPlace
AbbVie Stock: A Perfect Dip for Investors to Buy
Via MarketBeat
Topics ETFs
7 Safe Haven Stocks to Buy Before the Next Market Correction
Via InvestorPlace
7 Dividend Aristocrats That Will Have Investors in High-Yield Heaven
Via InvestorPlace
Topics Stocks
Exposures US Equities
Johnson & Johnson's Cell Therapy Carvykti Shows Better Survival Rate In Pretreated Blood Cancer Patients
Via Benzinga
Biotech Stock Breakout: IBB Eyes Resistance with Amgen and Vertex
Via MarketBeat
Topics ETFs
Exposures COVID-19
Court Rules Against Johnson & Johnson In Talcum Powder Cancer Study Case
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
JNJ Should Rally Soon Or See 3 Swings Higher At Least
Via Talk Markets
5 Biggest Winners, 5 Biggest Losers From Dow Jones Industrial Average In First Half 2024
Via Benzinga
Topics Stocks
Exposures US Equities
"Rule Breaker Investing" Mailbag: Talking Stocks and Options
Via The Motley Fool
3 Retirement All-Stars for Steady Growth and Income
Via InvestorPlace
Topics Retirement
Exposures Pension
3 Dividend Stocks Yielding Over 3% With Multi-Decade Payout Growth Streaks
Via InvestorPlace
Judge Blocks Cancer Victims' Attempt To Stop Johnson & Johnson Bankruptcy Plan
Via Benzinga
Topics Bankruptcy Lawsuit
Exposures Financial Legal
3 Magnificent Stocks Retirees Can Buy and Hold Forever
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.